Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here
- 9 February 2018
- Vol. 124 (10), 2086-2103
- https://doi.org/10.1002/cncr.31272
Abstract
Advances in cancer immunotherapy and a growing body of research have focused on the role of the antitumor response in breast cancer. Triple-negative breast cancer (TNBC) is the most immunogenic breast cancer subtype, and there is strong evidence that tumor-infiltrating lymphocytes in TNBC have prognostic value and are associated with clinical outcome and improved survival. Evading antitumor immunity is a hallmark for the development and progression of cancer. Immunotherapy studies have focused on the role of the programmed cell death-1 (PD-1) receptor/programmed death-ligand 1 (PD-L1) pathway in maintaining immunosuppression in the tumor microenvironment. Blockade of the PD-1/PD-L1 axis has emerged as a promising therapeutic option to enhance antitumor immunity and is actively being investigated in TNBC, with encouraging results. In this article, the authors review the current literature on checkpoint inhibitors in TNBC with a focus on PD-1/PD-L1 antibodies and discuss combination strategies and novel approaches for improving antitumor immunity and clinical outcome. Cancer 2018. © 2018 American Cancer Society.Keywords
Funding Information
- Shifrin-Myers Breast Cancer Discovery Fund (DOH01-Rowley-2015-00,076)
This publication has 81 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerThe New England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- Immunologic Correlates of the Abscopal Effect in a Patient with MelanomaThe New England Journal of Medicine, 2012
- Immune Inhibitory Molecules LAG-3 and PD-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune EscapeCancer Research, 2012
- Microbiome and MalignancyCell Host & Microbe, 2011
- Leukocyte composition of human breast cancerProceedings of the National Academy of Sciences of the United States of America, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- CD4+ T-Cell Help in the Tumor Milieu Is Required for Recruitment and Cytolytic Function of CD8+ T LymphocytesCancer Research, 2010
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityThe Journal of Experimental Medicine, 2010
- Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine modelBritish Journal of Cancer, 2009